The Effects Of A Synbiotic Product On

The Blood Lipid Prof,Ile And Red Blood

Cell Morphology Among

Hypercholesterolemic Subjects by Ooi , Lay Gaik
THE EFFECTS OF' A S\7NBIOTIC PRODUCT ON 
THE BLOOD LIPID PROF,ILE AND RED BLOOD 
CELL MORPHOLOGY Al\tiONG 
HYPERCHOLESTEROLEMIC SUBJECTS 
by 
OOILAYGAIK 
Thesis submitted in fulfillment of the requirements 
for the Degree of 
Master of Science 
AUGUST 2010 
------------------------------'Acknowledgment 
ACKNOWLEDGEMENT 
First and foremost, I would like to express my deep and sincere gratitude to my 
principal supervisor, Dr. Liong Min Tze, for her persistent support and invaluable 
guidance throughout my study. Her constructive knowledge and extensive discussions 
around my work have been of great value for me. Special thanks to my co-supervisor, 
Assoc. Prof. Dr. Rosma Ahmad and Prof. Yuen Kah Hay for their valuable advice.· 
I also wish to thank the laboratory manager, Mr. Zainodin Osman and all the 
laboratory assistants, Mr. Abdul Ghoni, Mr. Alfenddi bin Jamaluddin, Mr. Azmaizan 
Yaakub, Mrs. Mazura Md Nayan, Mrs. Najmah Hamid, Mr. Khairul Azhar bin Jaafar, 
Mr. Mohd Nazeef Ahmad, Mr. Ahmad Rizal bin Abdul Rahim and Mr. Johari Othman 
for their technical help. A note of gratitude also goes to my colleagues, Mr. Lim Ting Jin 
Ms. Yeo Siok Koon, Ms. Ewe Joo Ann, Ms. Fung Wai Yee, Ms. Kuan Chiu Yin, Ms. 
Lye Huey Shi and Mr. Teh Sue Siang who have provided me with inspiration, advice 
and encouragement. I would also like to thank the staff nurses in Pusat Kesihatan USM 
for their professional assistance in blood drawing throughout this research. 
I also gratefully acknowledge Universiti Sains Malaysia for their financial 
support as part of scholarship offered under scheme of USM Fellowship, eScienceFund 
Grant (305/PTEKIND/613218) provided by the Malaysian Ministry of Science, 
Technology and Innovation, and the USM RU Grant (1001/PTEKIND/833003). 
Last but not least, the most special thanks to my parents and family for their 
continuous support, understanding and encouragement when I needed them most. 
OOI LAY GA£K (AUGUST 2010) 
ii 
___________________________ Table of contents 
2.7 
2.8 
2.9 
Contradictory findings 
Dose-response effects 
Mechanisms of cholesterol-lowering effects 
2.8.1 Enzymatic deconjugation of bile acids 
2.8.2 Cholesterol binding to cell walls ofprobiotics 
2.8.3 Incorporation of cholesterol into the cellular membranes of 
probiotics during growth 
2.8.4 Conversion of cholesterol into coprostanol 
21 
27 
27 
29 
30 
31 
2.8.5 Alteration of lipid transporters 32 
2.8.6 The role ofprebiotics in modulating the cholesterol synthesis 36 
Safety of probiotics and prebiotics 
2.9.1 Systemic infections and deleterious metabolic activities 
37 
38 
2.9.2 Deconjugation of bile acids and secondary bile acids cytotoxicity 40 
2.9.3 Adverse immunological effects 41 
2.9.4 Genetic interactions between probiotics and intestinal microbes 41 
2.9.5 Prebiotics: Safety 43 
2.10 Cholesterol effects on irregularities of red blood cells (RBC) 45 
CHAPTER 3- MATERIALS AND METHODS 
3.1 
3.2 
3.3 
3.4 
Source of pro biotic culture and prebiotic 
Production of synbiotic capsules 
Recruitment of subjects 
Study protocol 
iv 
49 
50 
51 
51 
52 
__________________________ Table of contents 
Analyses 
3.5.1 Plasma lipid profiles 
3.5.2 Lipoprotein subfractions 
3.5.3 Plasma bile acids 
3.5.4 Red blood cell (RBC) counts 
3.5.5 Scanning electron microscopy (SEM) 
3.5.6 Preparation of RBC (ghost) membranes 
3.5.7 Determination of membrane fluidity by 
fluorescence anisotropy (FAn) 
3.5.8 Lipid extraction 
(for the determination of cholesterol and phospholipids) 
3.5.9 Determination of fatty acid methyl ester (FAME) 
Statistical analysis 
CHAPTER 4 -RESULTS AND DISCUSSIONS 
4.1 Body weights and dietary intake 
4.2 Plasma lipid profiles 
4.3 Lipoprotein subfractions 
4.4 Plasma bile acids 
4.5 Scanning electron microscopy (SEM) 
4.6 Ratio of cholesterol/phospholipids 
4.7 Fatty acid methyl ester (FAME) 
4.8 Fluorescence anisotropy (FAn) of RBC membrane 
v 
54 
54 
56 
58 
58 
59 
60 
60 
61 
61 
62 
63 
64 
67 
69 
77 
80 
83 
86 
90 
_________________________ Table of contents 
CHAPTER 5- CONCLUSIONS AND RECOMMENDATIONS 94 
REFERENCES 98 
LIST OF PUBLICATIONS 120 
_AfPENDICES 131 
vi 
:.....:...-----------------------------·--u• of tables 
Table 4.3 
Table 4.4 
Table 4.5 
Table 4.6 
LIST OF TABLES 
Page 
Studies supporting the lack of significant improvements in 20 
lipid profiles by prebiotics I synbiotics supplementation 
Dose-response effects of different probiotic strains on lipid 23 
profiles. 
Dose-response effects of different prebiotics on lipid profiles 25 
Isolation of lactobacilli from clinical cases of systemic 39 
infections 
Mean age and gender of hypercholesterolemic subjects 64 
(n=32) recruited for this study 
Effect of the synbiotic on body weight and Body Mass Index 65 
(BMI) ofhypercholesterolemic subjects (n=32) for 12 weeks 
Energy and nutrient intake of hypercholesterolemic subjects 
(n=32) for 12 weeks 
Effect of the synbiotic on lipid profiles of the 
hypercholesterolemic subjects (n=32) for 12 weeks 
Effect of the synbiotic product on conjugated, deconjugated, 
primary and secondary bile of hypercholesterolemic subjects 
(n=32) for 12 weeks 
Effect of the supplementation of the synbiotic product on 
ratio of cholesterol/phospholipids in RBC membranes of 
vii 
66 
68 
79 
85 
~--------------------------·List of tables 
hypercholesterolemic human (n=32) for 12 weeks 
Effect of the synbiotic product on FAME in RBC membranes 87 
ofhypercholesterolemic human (n=32) for 12 weeks 
Effect of the supplementation of the synbiotic product on 93 
fluorescence anisotropy (FAn) of RBC ghosts m 
hypercholesterolemic human (n=32) for 12 weeks 
viii 
,:__ ___________________________ ,~·~·of figures 
Figure 4.3 
Figure 4.4 
Figure 4.5 
Figure 4.6 
LIST OF FIGURES 
Page 
Cholesterol as the precursor for the synthesis of new bile acids and the 28 
cholesterol-lowering role of bile salt hydrolase. 
Scanning electron micrograph of Lactobacillus bulgaricus cultivated in 29 
(A) media without cholesterol and (B) broth supplemented with 
cholesterol (100 mM). 
Structure of plasma lipoprotein. 
Stmcture of red blood cells (RBC) membrane. 
Subfraction of VLDL-cholesterol of hypercholesterolemic subjects 
supplemented with the control and synbiotic for 12 weeks. 
Sub fraction of IDL-cholesterol of hypercholesterolemic subjects 
supplemented with the control and synbiotic for 12 weeks. 
Subfraction of LD L-cholesterol of hypercholesterolemic subjects 
supplemented with the control and synbiotic for 12 weeks. 
Subfraction of HDL-cholesterol of hypercholesterolemic subjects 
supplemented with the control and synbiotic for 12 weeks. 
RBC from subject on the placebo at week-0 (A), at week-6 (B) and at 
week-12 (C); and from subject on the synbiotic product at week-0 (D), at 
week-6 (E) and at week-12 (F). 
Location of fluorescence probes in RBC membrane using FAn. 
ix 
33 
46 
70 
72 
74 
76 
82 
90 
of publications 
LIST OF PUBLICATIONS 
Page 
Yeo, S. K., Ooi, L. G., Lim, T. J., & Liong, M. T. (2009). 123 
Antihypertensive properties of plant-based prebiotics. Int J Mol Sci, 10, 
3517-3530. (lSI with impact factor of 1.47; Published) 
Ooi, L. G., Ahmad, R., Yuen, K. H., & Liong, M. T. (2010). 124 
Hypocholesterolemic effects of probiotic-fermented dairy products. 
Milchwissenschaft (lSI with impact factor of 0.39; In-press) 
Ooi, L. G., & Liong, M. T. (2010). Cholesterol-lowering effects of 125 
probiotics and prebiotics: A review of in vivo and in vitro findings. Int J 
Mol Sci, 11, 2499-2522. (lSI with impact factor of 1.47; Published) 
Ooi, L. G., Ahmad, R., Yuen, K. H., & Liong, M. T. (2010). L. 126 
acidophilus CH0-220 and inulin reduced plasma total- and LDL-
cholesterol via alteration of lipid transporters. J Dairy Sci. (lSI with 
impact factor of 2.24; Accepted) 
Publication Ooi, L. G., Bhat, R., Ahmad, R., Yuen, K. H., & Liong, M. T. (2010). A 127 
.5 Lactobacillus acidophilus CH0-220 and inulin synbiotic improves 
irregularity of RBC. J Dairy Sci. (lSI with impact factor of 2.24; In-
press) 
Publication Ooi, L. G., R., Ahmad, Yuen, K. H., & Liong, M. T. (2010). Improved 128 
6 lipid profiles in human subjects upon consumption of bile salt hydrolase-
producing probiotics. BIT's 1st Inaugural Symposium on Enzymes. & 
Biocatalysis-2010. 22-24 April2010, Shanghai, China. (Oral) 
Publication Ooi, L. G., R., Ahrnad, Yuen, K. H., & Liong, M. T. (2010). Effects of 129 
X 
..,..:._ _______________________ .List of publications 
bile salt hydrolase on plasma bile concentrations in hypercholesterolemic 
subjects. BIT's 1st Inaugural Symposium on Enzymes & Biocatalysis-
2010. 22-24 April2010, Shanghai, China. (Poster) 
Liong, M. T., Ooi, L. G., Lim, T. J., Yeo, S. K., Ewe, J. A., & Lye, H. S. 130 
(2010). Probiotics and Enteric Cancers. In: Probiotics and Enteric 
Infections (Koninkx, JFJG, Marinsek-Logar, R and Malago, JJ, eds). 
Berlin: Springer-Verlag. (In-press) 
xi 
Appendix 23 
of appendices 
LIST OF APPENDICES 
Page 
Flyer of the advertisement in the present study 132 
Poster of the advertisement in the present study 133 
The food/dietary diary 134 
The health history form 135-137 
Letter of ethics approval by Joint Ethics Committee of School of 138-139 
Pharmaceutical Sciences USM-Hospital Lam Wah Ee 
140-144 
145-151 
The form of laboratory assessment 152 
The form of body weight assessment 153 
The assessment form of adverse effect (if any) 154 
Appendix 24-25 Good Clinical Practice (GCP) certification 155-156 
. Appendix 26 
Appendix 27 
The manufacturer's license of Malaysian Pharmaceutical Industries 
Sdn. Bhd. (Penang, Malaysia) 
The manufacturer's license of Po lens (M) Sdn. Bhd. (Selangor, 
Malaysia) 
xii 
157 
158 
L.;:...---------------------------'--''"' of appendices 
Source of vegetable capsules used for synbiotic encapsulation 159 
[supplied by Halalgel (M) Sdn. Bhd., Kedah, Malaysia] 
The biodata of 32 subjects recruited in the present study (Year 2008) 160 
xiii 
.:...__---------------------·--------- ofabbreviations 
Abbreviations 
ANOVA 
ANS 
BMI 
BSH 
CE 
CETP 
CFU 
cos 
CVD 
DNA 
DPH 
F 
FAME 
FAn 
FAO 
FDA 
FOS 
LIST OF ABBREVIATIONS 
Full Name 
Analysis of variance 
8-anilino-1-napthalenesulfonic acid 
Body Mass Index 
Bile-salt hydrolase 
Cholesteryl ester 
Cholesteryl ester transfer protein 
Colony forming unit 
Chito-oligosaccharide 
Cardiovascular diseases 
Deoxyribonucleic acid 
1, 6-diphenyl-1, 3, 5-hexatriene 
Female 
Fatty acid methyl ester 
Fluorescence anisotropy 
Food and Agriculture Organization 
Food and Drug Administration 
Fructooligosaccharides 
xiv 
GC 
GLP 
GMP 
GOS 
HCl 
HDL 
LCAT 
LDL 
IDL 
M 
MRS broth 
NaCl-KBr 
PCR 
RBC 
RCT 
RSM 
Gas chromatography 
Good Laboratory Practice 
Good Manufacturing Practice 
Galactooligosaccharide 
Hydrochloric acid 
High-density lipoprotein 
Lecithin-cholesterol acyltransferase 
Low-density lipoprotein 
Intermediate-density lipoprotein 
Male 
de Mann- Rogosa- Sharpe broth 
Sodium chloride-Potassium bromide 
Polymerase chain reaction 
Red blood cells 
Reverse cholesterol transport 
Response surface methodology 
XV 
of abbreviations 
List of abbreviations 
SCFAs Short-chain fatty acids 
SD Standard deviation 
SEM Scanning electron microscopy 
SFA Saturated fatty acids 
TMA-DPH 1-( 4-trimethylammonium)-6-phenyl-1, 3, 5-hexatriene 
UFA Unsaturated fatty acids 
VLDL Very low-density lipoprotein 
WHO World Health Organization 
xos X ylooligosaccharides 
xvi 
----------------------------------------------------------__ ,Abstrak 
KESAN SUATU PRODUK SINBIOTIK KE ATAS PROFIL LIPID DARAH DAN 
MORFOLOGI SEL DARAH MERAH DIKALANGAN SUBJEK 
HIPERKOLESTEROLEMIA 
ABSTRAK 
Produk sinbiotik telah digunakan secara konvensional untuk meningkatkan kesihatan 
pencemaan. Meskipun banyak kajian telah menemui potensi baru produk sinbiotik 
, 
namun demikian maklumat yang sedia ada berkenaan dengan kesan sinbiotik ke atas 
penurunan kandungan kolesterol darah dan mekanisme yang terlibat adalah terhad. 
Kajian secara rawak, 'double-blind' dengan placebo sebagai kawalan bertujuan untuk 
I 
mengkaji kesan suatu produk sinbiotik ke atas profil lipid di kalangan subjek 
hiperkolesterolemia dan mekanisme yang terlibat. Tiga puluh dua subjek 
hiperkolesterolemia dengan aras kolesterol plasma awal pada 5.70 ± 0.32 mmol/L telah 
diagihkan secara rawak kepada dua kumpulan untuk menerima samada empat kapsul 
sinbiotik ('Lactobacillus acidophilus' -CHO 220 dan inulin) atau plasebo setiap hari. 
Sampel darah puasa diambilkan pada minggu ke-0, 6 dan 12 untuk analisis lipid, 
lipoprotein, asid hempedu dan sel-sel darah merah. Kumpulan sinbiotik menunjukkan 
penurunan signifikan keatas jumlah kolesterol plasma dan kolesterol lipoprotein 
kepadatan rendah plasma sebanyak 7.84% dan 9.27%, masing-masing pada minggu ke-
12 (P < 0.05) manakala kumpulan kawalan tidak menunjukkan sebarang perbezaan Yang 
signifikan. 'Cholesteryl ester' ('CE') dalam zarah lipoprotein kepadatan tinggi bagi 
kumpulan sinbiotik adalah lebih tinggi daripada kumpulan kawalan (P < 0.05) 
menunjukkan bahawa peningkatan pengangkutan kolesterol dengan lipoprotein 
kepadatan tinggi dalam bentuk 'CE' kepada hepar untuk dihidrolisis. Kumpulan 
sinbiotik juga mempunyai kepekatan 'CE' dan kolesterol yang lebih rendah dalam zarah 
xvii 
_____________________________ Abstrak 
lipoprotein kepadatan rendah dibandingkan dengan kawalan (P < 0.05). Meskipun 
'Lactobacillus acidophilus' CH0-220 boleh menyahkonjugasikan asid hempedu, namun 
perbezaan kepekatan asid hempedu dalam plasma antara kumpulan sinbiotik dan 
kawalan yang tidak signifikan (P > 0.05) dalam kajian kami telah menunjukkan bahawa 
produk sinbiotik tersebut bebas daripada isu ketoksikan asid hempedu. Kumpulan yang 
dibekalkan dengan produk sinbiotik telah menunjukkan penurunan aras jumlah 
kolesterol plasma dan kolesterol lipoprotein kepadatan rendah plasma, mungkin melalui 
sistem pengangkut lipid. Mikroskopi electron perskanan menunjukkan bahawa 
morfologi sel-sel darah merah telah diperbaiki melalui suplementasi sinbiotik. 
I 
Suplementasi sinbiotik telah menurunkan nisbah kolesterol/fosfolipid dengan signifikan 
(P < 0.05) dalam membran sel-sel darah merah sebanyak 47.02% selepas 12 minggu, 
manakala kumpulan kawalan tidak menunjukkan sebarang perubahan yang signifikan. 
Kajian ini juga menunjukkan bahawa suplementasi sinbiotik mengurangkan kepekatan 
asid lemak tepu, peningkatan asid lemak tak tepu dan meningkatkan nisbah asid lemak 
tak tepu/asid lemak tepu secara signifikan (P < 0.05 ) selepas 12 minggu manakala 
kumpulan kawalan menunjukkan perubahan yang tidak signifikan. Perubahan membran 
sel-sel darah merah dikaji dengan menggunakan kaedah anisotropi pendafluoran dan 
proba pendafluoran dengan afiniti yang berbeza untuk bahagian fosfolipid yang 
berlainan. Penurunan bacaan bagi acid 8-anilino-1-naptalinsulfonik, 1, 6-difenil-1, 3, 5-
hexatrin dan 1-(4-trimetilammonium)- 6-difenil-1, 3, 5-hexatrin secara signifikan (P < 
0.05) dalam kumpulan sinbiotik selepas 12 minggu menunjukkan peningkatan 
kebendaliran membran dan pengurangan gumpalan kolesterol dalam membran sel-sel 
darah merah dalam kumpulan sinbiotik. 
xviii 
Abstract --------------------------------------------------------~ 
THE EFFECTS OF A SYNBIOTIC PRODUCT ON THE BLOOD LIPID 
PROFILE AND RED BLOOD CELL MORPHOLOGY AMONG 
HYPERCHOLESTEROLEMIC SUBJECTS 
ABSTRACT 
Synbiotics have been ·Conventionally used to improve gastrointestinal health. Although 
current researches have found new health potentials of synbiotics, little information is 
available on possible cholesterol-lowering effects and the mechanisms involved. This 
randomized, double-blind and placebo-controlled study investigated the effects of a 
synbiotic product on the lipid profiles of hypercholesterolemic subjects and the possible 
I 
mechanisms entailed. Thirty-two hypercholesterolemic subjects with initial mean plasma 
cholesterol levels of 5.70 ± 0.32 mmol/L were randomly allocated to two groups and 
were given four capsules of either synbiotic (Lactobacillus acidophilus CH0-220 and 
inulin) or placebo daily. Fasting blood samples were collected at weeks 0, 6 and 12 for 
lipid, lipoprotein, bile and red blood cells (RBC) analyses. The synbiotic group showed 
plasma total- and LDL cholesterol reductions by 7.84% and 9.27%, respectively over 12 
weeks (P < 0.05) while the control showed insignificant difference. Cholesteryl ester 
(CE) in the HDL subfraction in the synbiotic group was higher than the control (P < 
0.05), indicating increased transport of cholesterol by HDL in the form of CE to the liver 
for hydrolysis. The synbiotic group also had lower CE and cholesterol concentrations in 
the LDL subfraction compared to the control (P < 0.05). Although Lactobacillus 
acidophilus CH0-220 could deconjugate bile, our results showed insignificant (P > 0.05) 
difference in bile acids concentrations between the synbiotic and the control groups, 
indicating that the synbiotic product 1s safe from bile-related toxicity. The synbiotic 
product lowered plasma total- and LDL-cholesterol levels, possibly via modifying the 
xix 
Abstract --------------------------------------------------------~ 
interconnected pathways of lipid transporters. Scanning electron microscopy (SEM) 
showed spur RBC was improved upon supplementation of the synbiotic. The 
supplementation of synbiotic significantly (P < 0.05) reduced the 
cholesterol/phospholipids ratio of the RBC membrane by 47.02% over 12 weeks, while 
the control showed insignificant changes. Our present study also showed that the 
synbiotic supplementation reduced saturated fatty acids (SFA) concentration, increa.Sed 
unsaturated fatty acids (UFA) and increased _UFNSFA ratio (P < 0.05) over 12 weeks 
while the control showed insignificant changes. The alteration of RBC membrane was 
assessed using fluorescence anisotropy (FAn) and fluorescence probes with different 
I 
affinities for varying sections of the membrane phospholipid bilayer. A significant (P < 
0.05) decrease in FAn of 8-anilino-1-napthalenesulfonic acid (ANS), 1, 6-diphenyl-1, 3, 
5-hexatriene (DPH) and 1-(4-trimethylammonium)-6-phenyl-1, 3, 5-hexatriene (TMA-
DPH) was observed in the synbiotic group compared to the control over 12 weeks, 
suggesting increased membrane fluidity and reduced cholesterol enrichment in the RBC 
membrane. 
XX 
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CHAPTER I 
INTRODUCTION 
1 
I 
----------------------------------------------------------'Chap~rl 
1.1 Background 
Hypercholesterolemia is a metabolic derangement with the presence of high 
levels of cholesterol in the blood which can lead to many forms of diseases, most 
remarkably cardiovascular diseases (CVD) (Austin eta!., 2004). CVD is one of the most 
prevalent diseases in the developing countries and the urgency for its management is 
increasing as the incidence in these countries grows each year (Reddy and Yusuf, 1998). 
In 2003, according to the World Health Organization (WHO), CVD made up 16.7 
million or 29.2% of total global deaths and CVD will be the leading cause of death in 
developing countries by 2010 (WHO 2003a). High plood cholesterol levels can be 
reduced by medication, exercise or dietary modification including the supplementation 
of probiotic and/or prebiotic (Neuhouser et a!., 2002). Probiotics are 'living microbial 
supplements that beneficially affect the host animals by improving its intestinal 
microbial balances' (FAO and WHO, 2001). They are normally known as 'friendly 
bacteria' such as bifidobacteria and lactobacilli, and can be found in the human gut. 
Prebiotics are 'indigestible fermented food substrates that selectively stimulate 
the growth, composition and activity of microjlora in gastrointestinal tract and thus 
improve hosts' health and well-being' (Roberfroid, 2007). When probiotics and 
prebiotics are used in combination, they are known as 'synbiotics'. Probiotics and 
prebiotics have been well-documented for their roles in enhancing gastrointestinal health. 
However, recent advances in research have documented new potentials of probiotics and 
prebiotics on other aspects of human health. This includes cholesterol-lowering effects 
and the prospective of establishing probiotics and prebiotics as non-drug alternatives for 
the management of hypercholesterolemia. 
2 
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Past studies have shown that the administrations of probiotics and prebiotics are 
effective in improving lipid profiles such as the reduction of serum total cholesterol, 
triglycerides and LDL-cholesterol. Probiotic strains such as Lactobacillus acidophilus 
(Fukushima eta!., 1999; Lubbadeh et al., 1999), Lactobacillus plantarum (Naruszewicz 
et al., 2002; Ha et al., 2006; Jeun et al., 2010), Bifidobacterium longum (Xiao et al., 
2003; Abd El-Gawad et al., 2005), Lactobacillus casei (Bertazzoni-Minelli eta!., 2004), 
Enterococcus faecium and Streptococcus thermophilus (Agerholm-Larsen et al., 2000) 
have been found to positively improve blood lipid profiles, especially total cholesterol 
and LDL-cholesterol. Prebiotics such as inulin (Causey eta!. 2000; Letexier et al., 200~) 
and fructooligosaccharides (Alles et al., 1999) have also been shown to positively 
modulate lipid profiles. Despite these findings, limited studies have emphasized on the 
use of synbiotics (probiotics and prebiotics in combination) to augment a cholesterol-
lowering effect in humans. 
In addition, past studies have associated cholesterol-enriched diets with 
hypercholesterolemia, which in turn causes morphological abnormality in red blood cells 
(RBC) leading to their decreased life span (Nayak et al., 2008). Such abnormality can 
subsequently increase the risk of impairing the physical function and microcirculation of 
RBC. However, to our knowledge, the exact mechanisms of probiotics, prebiotics and 
synbiotics in lowering cholesterol and improvement of irregularities of RBC remain 
unclear. Most of the documented work emphasized on proving a cholesterol-lowering 
effect and little is known on the underlying mechanisms. 
3 
_____________________________ Chapter I 
Although the combination of probiotic and/or prebiotics (synbiotic) had been 
developed and showed promising in vivo cholesterol-lowering effect in animal models 
(Lichtman et al., 1999; Gallaher et al., 2000; Lin et al., 2004; Madsen et al., 2008; 
Patterson et al., 2008); such transferability of a similar effect in humans have yet to be 
evaluated, and the underlying mechanisms, elucidated. Considering that past studies 
have reported positive effects of probiotics, prebiotics and synbiotics on serum · 
cholesterol (Nguyen et al., 2007; Zhang et al., 2007; Wong et al., 2010), we 
hypothesized that these supplements could also positively improve morphological 
irregularities of the RBC brought about by hypercholesterolemia. Although many 
positive evidences have surfaced on the use of the probiotics, prebiotics and synbiotics 
to reduce blood' cholesterol levels, to our knowledge, no attempt has been made to 
evaluate their effects on irregularities of RBC in humans. 
1.2 Aim and objective of research 
Many strains of L. acidophilus have been identified for use as dietary adjuncts, 
mainly attributed to their long history of safe use and in-vitro cholesterol-lowering 
effects (Gupta eta/., 1996). The usage of inulin has also been widely highlighted due to 
its safe consumption (Carabin and Flamm, 1999) and its application in cholesterol-
lowering effects (Davidson et al., 1998; Brighenti, 2007). The cholesterol-lowering 
effects of synbiotics containing L. acidophilus and inulin and/or inulin-type prebiotics 
have also been reported (Schaafsma et al., 1998; KieBling et al., 2002). In addition, 
strains of L. acidophilus have also been deposited as L. casei, L. paracasei and L. 
johnsonii elsewhere (ATCC, 2010). All of these strains have also shown cholesterol-
4 
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lowering effects in in-vivo models when used in combination with inulin and inulin-type 
prebiotics (Bertazzoni-Minelli et al., 2004; Sarmiento-Rubiano et al., 2007). 
The aim of this study was to investigate the effects of a synbiotic product 
containing L. acidophilus CH0-220 and inulin on the plasma lipid profiles of 
hypercholesterolemic subjects. The effects of the synbiotic product on plasma lipid 
transporters and the possible mechanisms involved were evaluated. The effect of the 
synbiotic product on bile conversion was also assessed. In addition, this study was also 
aimed to evaluate the effect of this synbiotic product on the morphological irregularities 
of RBC induced by hypercholesterolemia. The morphology of RBC, ratio of 
cholesterol/phospholipids, membrane fluidity properties and fatty acid profiles of RBC 
were thus investigated. 
The specific objectives of this study were: 
1. To assess the effects of a synbiotic product on the human plasma lipid profiles such 
as plasma total cholesterol, triglycerides, LDL-cholesterol and HDL-cholesterol. 
2. To evaluate the changes in the compositions of triglycerides, cholesteryl ester, 
protein, total-cholesterol, free cholesterol and phospholipids that occurring in the 
subfractions of human lipoproteins such as Very Low Density Lipoprotein (VLDL), 
Intermediate Density Lipoprotein (IDL), Low Density Lipoprotein (LDL) and High 
Density Lipoprotein (HDL) upon the consumption of the synbiotic product. 
3. To assess the effects of the synbiotic product on the hypercholesterolemia-induced 
morphological irregularities of the human RBC. 
5 
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CHAPTER2 
LITERATURE REVIEW 
6 
______________________________ Chapter2 
2.1 Health facts 
The World Health Organization (WHO) (2009) predicted that by 2030, 
cardiovascular diseases will remain the leading causes of death, affecting approximately 
23.6 million people around the world. It was reported that hypercholesterolemia [a 
condition whereby it has been associated with higher than normal total cholesterol (~ 5.2 
mmol/L) and Low Density Lipoprotein-cholesterol (~2.6 mmol/L)] contributed to 45% 
of heart attacks in Western Europe and 35% of heart attacks in Central and Eastern 
Europe from 1999 to 2003 (Yusuf et al., 2004). The risk of heart attack is three times 
higher in those with hypercholesterolemia compared to those who have normal blood 
lipid profiles. The WHO (2003b) delineated that unhealthy diets that are high in fat, salt 
and simple sugar; and low· in complex carbohydrates, fruits and vegetables lead to 
increased risk of cardiovascular diseases. Hypercholesterolemia is considered one of the 
major risk factors of cardiovascular disease, as approximately 90% of patients with 
cardiovascular problems have prior exposure to unfavorable blood cholesterol levels, 
especially high levels of total cholesterol and LDL-cholesterol, in addition to 
hypertension, obesity and diabetes (Greenland et al., 2003). Clinical trials have indicated 
that the rates of coronary heart disease could be reduced by reducing blood cholesterol 
levels (Reese et al., 2001 ). Population-based data have shown that a 10 percent decrease 
in total cholesterol levels could result in an estimated 30 percent reduction in the 
incidence of coronary heart disease (Reese et a/., 2001 ), while every one percent of 
reduction in LDL-cholesterol levels could reduce the relative risk for coronary heart 
disease by approximately one percent (Grundy et al., 2004). 
Parts of this literature review have been published: 
1. Yeo, S. K., Ooi, L. G., Lim, T. J., & Liong, M. T. (2009). Antihypertensive properties of 
plant-based prebiotics. Int J Mol Sci, l 0, 3517-3530. (IS I; Published) 
2. Ooi, L. G., Ahmad, R., Yuen, K. H., & Liong, fvt. T. (2010). Hypocholesterolemic effects of 
probiotic-fermented dairy products. Milchwissenschaft (lSI; In-press) 
3. Ooi, L. G., & Liong, M. T. (2010). Cholesterol-lowering effects ofprobiotics and prebiotics: 
A review of in vivo and in vitro findings. Int J Mol Sci, II, 2499-2522. (ISI; Published) 
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2.2 Probiotics, prebiotics, synbiotics and cholesterol 
People affected with hypercholesterolemia may avert the use of cholesterol-
lowering drugs by practising dietary control or supplementation of probiotics and/or 
prebiotics. Probiotics are 'living microbial supplements that beneficially affect the host 
animals by improving its intestinal microbial balances' (FAO and WHO, 2001). 
Prebiotics are 'indigestible fermented food substrates that selectively stimulate the 
growth, composition and activity of microjlora in gastrointestinal tract and thus improve 
hosts' health and well-being' (Roberfroid, 2007). When probiotics and prebiotics are 
used in combination, they are known as 'synbiotics'. The use of probiotics and 
prebiotics has only acquired scientific recognition in recent years although their 
applications as functional foods have been well-established throughout generations. In 
the interest of their promising effects on health and well being, probiotics and prebiotics 
have become increasingly recognized as supplements for human consumption. 
Lactobacillus and Bifidobacterium are common genera of probiotics and have 
been documented to exert health-promoting effects which include improvement of lipid 
profiles (Pereira and Gibson, 2002a, b), strengthening of the immune system (Galdeano 
et al., 2007), alleviation of diarrhoea (Hickson et al., 2007), improvement of lactose 
intolerance (Landon et al., 2006), antihypertensive effects (Yeo . and Liong, 201 0) 
prevention of cancer (Hirayama and Rafter, 2000), antioxidative effects (Songisepp et 
al., 2004), reduction of dermatitis symptoms (Weston et al., 2005), facilitation of 
mineral absorption (Scholz-Ahrens et al., 2007), amelioration of arthritis (Baharav et al., 
2004), reduction of allergic symptoms (Ouwehand, 2007) and improvement of 
vulvovaginal candidiasis in women (Falagas et al., 2006). 
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Fructooligosaccharides (FOS), inulin, oligofructose, lactulose, and 
galactooligosaccharides have been identified as prebiotics due to characteristics such as 
resistance to gastric acidity, hydrolysis by mammalian enzymes and are fermented by 
gastrointestinal microflora to further selectively stimulate the growth and/or activity of 
beneficial intestinal bacteria. FOS contains 2 to I 0 fructose units linked by glycosidic 
bonds, while inulin is a fructose polymer with P-(2-1) glycosidic linkages with chains of 
3 to 60 units. Both FOS and inulin are found abundantly in chicory and artichokes. The 
major component of chicory root is inulin. Inulin belongs to the fructan family, and 
occurs naturally as important storage carbohydrates. Other than chicory, fructans are 
also found present in artichokes, salsify, asparagus and onions (Kim and Shin, 1998). 
Generally, prebiotics offer promising health benefits such as improvement of lipid 
profile (Mortensen et a/., 2002), exerting positive impacts on gastrointestinal microtlora 
by promoting the growth of probiotics and/or inhibition of pathogenic microorganisms 
(Bielecka et al., 2002), stimulation of the immune system (Schley et a/., 2002), cancer 
prevention (Klinder et a/., 2004), stimulation of mineral absorption and bone stability 
(Scholz-Ahrens et a/., 2002) and treatment of irritable bowel - associated diarrhoeas 
(Cummings and Macfarlane, 2002). 
New compounds with gut resistant properties and selective. fermentability by 
intestinal microorganisms are continuingly being identified and developed as prebiotics 
(Gibson and Fuller. 2000). These include oligosaccharides (isomaltooligosaccharides, 
lactosucrose, xylooligosaccharides and glucooligosaccharides ), sugar . alcohols and 
polysaccharides (starch, resistant starch and modified starch) (Cummings et al., 2001 ). A 
combination of prebiotics and fermentable compounds are often used to strengthen 
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various health effects, including alteration of microbial population and production of 
short-chain fatty acids which may lead to the reduced incidence of gastrointestinal 
diseases (Topping and Clifton, 2001), cancers (Hinnebusch et a!., 2002) and 
cardiovascular diseases (Dewailly et al., 2001), and improvement of lipid profiles 
(Wolever eta!., 2002). 
Synbiotic products that are currently available on the market are often a 
combination of bifidobacteria or lactobacilli and fructooligosaccharides or inulins. There 
is a lack of studies relating to the lowering of cholesterol using synbiotics. Although 
studies have indicated that the administration of probiotics and/or prebiotics can reduce 
cholesterol level (Jeun et al., 2010; Trautwein eta!., 1998), controversies surfaced when 
some studies did not demonstrate the cholesterol-lowering potential of probiotics and/or 
prebiotics (Alles et al., 1999; Greany et al., 2008). 
Studies examining the efficacy of probiotics in reducing cholesterol often do not 
sufficiently address the mechanisms by which probiotics modulate cholesterol-lowering 
effects and the optimum dose, frequency, and duration of treatment for different 
probiotic strains. Several mechanisms have been hypothesized, which include enzymatic 
deconjugation of bile acids by bile-salt hydrolase of probiotics (Lambert et a!., 2008), 
cholesterol binding to cell walls of probiotics (Liong and Shah, 2005a), incorporation of 
cholesterol into the cellular membranes of probiotics during growth (Lye et al., 201 Oa), 
conversion of cholesterol into coprostanol (Lye et a!., 201 Ob) and production of short-
chain fatty acids upon fermentation by probiotics in the presence of prebiotics (De Preter 
et al., 2007). 
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Probiotics are generally known to be nonpathogenic but they could be infectious 
especially in the debilitated and immuno-compromised populations (Peret-Filho et al., 
1998). Some species of Lactobacillus, Bifidobacterium, Leuconostoc, Enterococcus and 
Pediococcus have been isolated from the infection sites (Land et al., 2005). Strains of 
probiotics have also been found to exhibit antibiotic resistance and have raised concerns 
on horizontal resistant genes transfer to the host and the pool of gastrointestinal 
pathogenic microflora (Huys et al., 2006). Considering this, the safety verification of 
probiotics used industrially and commercially is of utmost importance. 
2.3 Cholesterol-lowering potential of probiotics: In vivo evidence 
The use of animals and humans models to evaluate the effects of probiotics and 
prebiotics on serum cholesterol levels has been emphasized over the years. Human 
studies have shown promising evidence that well-established probiotics and/or prebiotics 
possess cholesterol-lowering effects, while new strains of probiotics or new types of 
prebiotics were evaluated in animal models for their potential cholesterol-lowering 
effects. Many studies were using rats (Gallaher et al., 2000; Shinnick et al., 1988), mice 
(Lichtman et al., 1999), hamsters (Lin et al., 2004), guinea pigs (Madsen et al., 2008) 
and pigs (Patterson et al., 2008) as models due to their similarities with humans in terms 
of cholesterol and bile acid metabolism, plasma lipoprotein distribution, and regulation 
of hepatic cholesterol enzymes (Fernandez et al., 2000). These animals also share an 
almost similar digestive anatomy and physiology, nutrient requirements, bioavailability 
a.t1d absorption, and metabolic processes with humans, making them useful experimental 
models for research applications (Patterson et al., 2008). Hence, the positive cholestero]-
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lowering effects shown in animal studies suggest a similar potential in humans. Human 
trial results that paralleled those obtained from animal studies further attested the 
transferability and reliability of results in selected animal models. 
In a study evaluating the effect of L. plantarum PH04 (isolated from infant feces) 
on cholesterol, Nguyen eta!. (2007) administered L. plantarum (at doses of 107 CFU/g 
per mouse per day) to twelve male hypercholesterolemic mice for 14 days. The authors 
found a significant (P < 0.05) reduction of total serum cholesterol (reduced by 7%) and 
triglycerides (reduced by 10%) compared to the control. In anoth~r study, Abd El-
Gawad et al. (2005) conducted a randomized, placebo-controlled and parallel designed 
study to assess the efficiency of buffalo milk-yogurts (fortified with Bijidobacterium 
longum Bb-46) in exerting a cholesterol-lowering effect. In the study, the authors fed 
forty-eight male albino hypercholesterolemic rats (average weight 80-100 g) with 50 g 
of yogurt [contained 0.07% (w/v) Bifidobacterium longum Bb-46] daily for 35 days. The 
administration of B. longum Bb-46-fermented buffalo milk-yogurt significantly reduced 
the concentration of total cholesterol by 50.3%, LDL-cholesterol by 56.3% and 
triglycerides by 51.2% compared to the control (P < 0.05). In another study, Fukushima 
et al. (1999) found that hypercholesterolemic male Fischer 344/Jcl rats (8 week old) fed 
with 30 g/kg of L. acidophilus-fermented rice bran significantly showed an improved 
lipid profile compared to the control (without L. acidophilus). In this 4-week study, the 
authors reported a significant (P < 0.05) reduction in serum total cholesterol and liver 
cholesterol of21.3% and 22.9%, respectively compared to the control. Similarly, Chiu et 
al. (2006) studied the effects of Lactobacillus-fennented milk on lipid metabolism using 
hamsters. The 8 weeks treatment involved a high-cholesterol diet plus: water (group 
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Ncontrol group), sterilized milk (group B), milk fermented by L. paracasei subsp. 
paracasei NTU 101 (group C), milk fermented by L. plantarum NTU 102 (group D) or 
milk fermented L. acidophilus BCRC 17010 (group E). The fermented-milk-feeding 
groups (group C, D and E) showed a significantly (P < 0.05) reduced serum cholesterol 
and LDL-cholesterol level compared to those of control group (group A) and milk-
feeding group (group B). These findings indicated that milk fermented by these three 
Lactobacillus strains were effective in reducing serum cholesterol concentration and 
LDL-cholesterollevel. 
The cholesterol-lowering potential of probiotics has also been evaluated using 
human subjects. Anderson et al. (1999) explored the effect of fermented milk containing 
, 
L. acidophilus L1 on serum cholesterol in hypercholesterolemic humans. This 
randomized, double-blind, placebo-controlled and crossover 1 0-week study was 
designed for forty-eight volunteers whose serum cholesterol values ranged from 5.40 to 
8.32 mmol/L. Daily consumption of 200 g of yogurt containing L. acidophilus L1 after 
each dinner contributed to a significant (P < 0.05) reduction in serum cholesterol 
concentration (-2.4%) compared to the placebo group. In another study, Xiao et al. 
(2003) evaluated the effects of a low-fat yogurt containing 108 CFU/g of B. longum BL1 
on lipid profiles of thirty-two subjects (baseline serum total cholesterol of 220-280 
mg/dl, body weight 55.4-81.8 kg, aged 28 to 60 years old). Results from this randomized, 
single-blind, placebo-controlled and parallel study showed a significant (P < 0.05) 
decline in serum total cholesterol, LDL-cholesterol and triglycerides after 4 weeks. The 
authors also observed a 14.5% increase in HDL-cholesterol when comparing to the 
control (yoghurt without B. longrun BL1; P < 0.05). In a randomized, double-blinded, 
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placebo-controlled and crossover-designed trial involving twenty-six healthy volunteers, 
Klein et al. (2008) determined the effect of yoghurt consumption (300 g/day) containing 
probiotic strains L. acidophilus 74-2 and Bifidobacterium anima/is subsp lactis DGCC 
420 on blood lipids. In this 1 0-week study, the authors reported a significant (P < 0.05) 
reduction in serum triglycerides of 11.6% compared to the control (plain yogurt without 
L. acidophilus 74-2 and Bifidobacterium anima/is subsp lactis DGCC 420). In another 
study, Agerholm-Larsen eta!. (2000) conducted an 8-week randomized, double-blind, 
placebo-controlled and parallel study involving seventy subjects. In this study, the 
authors observed a significant (P < 0.05) decline in LDL-cholesterol of 8.4% upon 
I 
consumption of 450 mL probiotics milk [containing of 6 x 107 CFU/mL of Enterococcus 
faecium (known probiotic isolated from human) and 1 x 109 CFU/mL of St. 
thermophilus (a common yogurt, culture)]. 
2.4 Cholesterol-lowering potential of prebiotics: Animal and human studies 
While the cholesterol-lowering effect of probiotics has been well-documented, 
prebiotics have also gained increasing attention in cholesterol studies, due to their role in 
promoting the growth of probiotics. Causey et al. (2000) conducted a randomized, 
double-blind and crossover study using hypercholesterolemic subjects to assess the 
effects of inulin from chicory root on blood cholesterol level. This study involved twelve 
men that were randomly assigned to two groups, namely the control group (consumed 
one pint of vanilla ice-cream without inulin daily) and the inulin group (consumed one 
pint of vanilla ice-cream containing 20 g of inulin daily). The 3-week study found that 
daily intake of 20 g of inulin significantly (P < 0.05) reduced serum triglycerides. 
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Similarly, another double-blind, randomized and placebo-controlled crossover study 
involving eight healthy volunteers with a daily consumption of 10 g of inulin for 3 
weeks has also reached the same conclusion (Letexier eta!., 2003). Plasma triglycerides 
concentration was significantly (P < 0.05) lower in the treatment group (with inulin) 
compared to the placebo group (without inulin) (Letexier et al., 2003). In another study, 
Brighenti et al. (1999) used a randomized, double-blind, placebo-controlled and parallel 
design trial involving twelve healthy male volunteers to study the effect of prebiotic on 
lipid profiles. In this 12-week trial, the authors found that the daily consumption of 50 g 
of a 
1
rice-based ready-to-eat cereal containing 18% inulin significantly (P < 0.05) 
reduced plasma total cholesterol and triglycerides by 7.9% (± 5.4) and 21.2% (± 7.8), 
respectively compared to the control. Similarly, Mortensen eta!. (2002) found that forty 
male mice fed with a purified diet with 10% of long-chained fructan for 16 weeks 
showed that the fructan significantly reduced blood cholesterol by 29.7% (P < 0.001), 
LDL-cholesterol concentration by 25.9% (P < 0.01), IDL-cholesterollevel by 39.4% (P 
< 0.001) and VLDL-cholesterol concentration by 37.3% (P < 0.05) compared to the 
control group. Davidson and Maki (1999) conducted a randomized, double-blind, 
placebo-controlled and crossover design trial for 12 weeks involving twenty-one healthy 
volunteers to study the effect of prebiotic on lipid profiles. The authors found that the 
daily consumption of 18 g/day of inulin-supplemented foods significantly reduced 
plasma total cholesterol (P < 0.02) and LDL-cholesterol (P < 0.005) by 8.7% (± 3.3) and 
14.4% (± 4.3), respectively compared to the control. Daubioul et al. (2002) administered 
1 0 g of fructan to male mice for eight weeks. The study involved sixteen male obese 
mice and the results showed that the fructan treatment significantly reduced (P < 0.05) 
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hepatic triacylgylcerol by 48% compared to the control group. In another study, 
Busserolles et al. (2003) found that male Wistar-Han rats fed with a diet containing 
oligofructose for four weeks showed a significant (P < 0.05) decline of 0.33% in hepatic 
triglycerides as compared to the control. 
Other indigestible and fermentable compounds such as germinated barley, 
oligodextrans, gluconic acid, lactose, glutamine, hemicellulose-rich substrates, resistant 
starch and its derivatives, lactoferrin-derived peptide, and N-acetylchitooligosaccharides 
(Gibson et al., 2004) have also been identified to exert prebiotic potentials with 
cholesterol-lowering effects. In a study evaluating the cholesterol-lowering effect of 
I 
resistant starch, Fernandez et al. (2000) administereq 10 g/lOOg of resistant starch into 
male Hartley guinea pigs for 4 weeks. This randomized, placebo-controlled and parallel 
designed study used sixteen male guinea pigs of 300-400 g body weight and the results 
showed that the resistant starch significantly reduced (P < 0.01) plasma cholesterol by 
27.4% and LDL-cholesterol concentration by 28.0% compared to the control group. In 
another randomized, placebo-controlled and parallel designed study, Wang et al. (2008) 
found that ten male hypercholesterolemic Wistar rats (7-week-old; mean body weight of 
210 ± 20 g) fed with starch from Chinese yam (Dioscorea opposita cv. Anguo) for 8 
weeks showed a significantly lower plasma total cholesterol, LDL-cholesterol and 
triglyceride (P < 0.05) than the control (32.8%, 27.5% and 46.2% lower, respectively). 
Favier et al. ( 1995) evaluated the cholesterol-lowering effects of ~- cyclodextrin in a 
randomized, placebo-controlled and parallel design trial involving ten male Wistar rats 
(mean body weight of 150 g). In this 21-day trial, the authors found that daily 
consumption of 25 g/kg of ~-cyclodextrin significantly (P < 0.05) reduced plasma 
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cholesterol and triglycerides by 25.9% and 35.0%, respectively, compared to the control 
group. 
2.5 Cholesterol-lowering potential of synbiotics: In vivo studies 
Studies have presented evidence of independent cholesterol-lowering effects of 
probiotics and prebiotics, leading to subsequent evaluations on synbiotics. The 
administration of a synbiotic product (containing L. acidophilus ATCC 4962, 
fructooligosaccharides, mannitol and inulin) to twenty-four hypercholesterolemic male 
pigs yielded prqmising cholesterol-lowering effects (Liang et a!., 2007). The authors 
reported a significant reduction of plasma total cholesterol (P < 0. 001 ), trigl ycerides (P 
< 0.001) and LDL·cholesterol (P < 0.045) in pigs consuming the synbiotic diet for 8 
weeks compared to the control. Kie~ling et al. (2002) evaluated the cholesterol-lowering 
effect of a synbiotic yoghurt (containing L. acidophilus 145, B. longum 913 and 
oligofructose) in a randomized, placebo-controlled and crossover study involving 
twenty-nine women. The authors found that the daily consumption of 300 g synbiotic 
yoghurt over 21 weeks significantly increased (P < 0.002) serum HDL-cholesterol by 
0.3 mmol!L, leading to an improved ratio of LDL/HDL. In another study, Schaafsma et 
a!. (1998) conducted a randomized, placebo-controlled, double blind and crossover 
designed study involving thirty volunteers (aged 33 to 64 years old; body weight of 
66.5-98.0 kg) with mean total cholesterol of 5.23 ± 1.03 mmol/L and LDL-cholesterol of 
3.42 ± 0.94 mmol/L. In this study, the authors observed that daily consumption of 375 
mL synbiotic milk [containing of 107 - 108 CFU/g of Lactobacillus acidophilus and 
2.5% (g/1 OOg) of fructooligosaccharides] resulted in a significant decline in total 
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cholesterol (P < 0.001), LDL-cholesterol (P < 0.005) and LDL/HDL ratio (P < 0.05) of 
4.4%, 5.4% and 5.3% respectively. 
2.6 Cholesterol-lowering potential of probiotics, prebiotics and synbiotics: 
Contradictory findings 
Although many studies have demonstrated convincing cholesterol-lowering 
effects of probiotics in both animals and humans, contradictory results have also 
surfaced. A study by Hatakka et a/. (2008) refuted the purported cholesterol-lowering 
effect of probiotics, and reported that the administration of L. rhamnosus LC705 (1 010 
I 
CFU/g per capsule; 2 capsules daily) did not influence blood lipid profiles in thirty-eight 
men with mean cholesterol levels of 6.2 mmol/L after a 4-week treatment period. In 
another study involving forty-six volunteers (aged 30 to 75 years old), Simons et a/. 
(2006) found that the consumption of Lactobacillus fermentum, (2 x 109 CFU per 
capsule; 4 capsules daily) did not contribute to any lipid profile changes after 10 weeks. 
Lewis and Burmeister (2005) conducted a randomized, placebo-controlled double blind 
and crossover designed study to determine the effect o( Lactobacillus acidophilus on 
human lipid profiles. In the study, eighty volunteers (aged 20 to 65 years old; baseline 
total cholesterol of> 5.0 mmol/L; mean Body Mass Index of27.8 kg/m2) consumed two 
capsules containing freeze-dried L. acidophilus (3 x 101° CFU/2 capsules) three times 
daily for a duration of 6 weeks, and crossed over for another 6 weeks after a 6-week 
washout period. The authors found that L. acidophilus capsules did not significantly 
change plasma total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides of 
the subjects. Thompson eta!. (1982) evaluated the effects of fermented dairy products 
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such as buttermilk fermented by Streptococcus (St.) cremoris and St. lactis, yogurt 
fermented by L. bulgaricus and St. thermophilus and milk inoculated with L. acidophilus 
on lipid profiles of sixty-eight healthy volunteers (26 male and 42 female). Lipid profiles 
of the subjects were not significantly changed after the 1 0-week trial. In another in vivo 
study involving seventy rats (with mean body weight of 146 g), Pulusani and Rao (1983) 
found that the feeding of milks fermented by L. acidophilus, L. bulgaricus or St. 
thermophilus did not contribute to any lipid profile changes after 4 weeks. The body 
lipids, liver lipids and liver cholesterol of the rats were also not affected. de Roos et a!. 
(1999) conducted a randorp.ized, placebo-controlled and parallel designed study to 
determine the effect of yogurt enriched with Lactobacillus acidophilus L-1 on human 
lipid profiles. In the study, seventy-eight male and female volunteers (aged 18 to 65 
years old) with mean serum cholesterol levels of 3.9 to 7.8 mmol/L and mean Body 
Mass Index of 21.2 to 27.2 kg/m2 were recruited. Subjects consumed 500 mL of either 
yogurt (enriched with L. acidophilus L-1 at concentration of 4.8 x 109 to 2. 7 x 1010 
CFU/500 mL) or control (plain yogurt without L. acidophilus L-1) daily for a duration of 
6 weeks. The authors found that yogurt supplemented with L. acidophilus L-1 did not 
significantly affect blood lipid profiles of the subjects. Total cholesterol, LDL-
cholesterol, HDL-cholesterol and triglycerides were not changed after .6 weeks. Similar 
controversies were also raised from studies evaluating the cholesterol-lowering 
properties of prebiotics and also when probiotics and prebiotics were used together 
(synbiotic) (Table 2.1). 
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Studies supporting the lack of significant improvements in lipid profiles by prebiotics I synbiotics supplementation 
ComJ>ound(s) _ _ _ Experimental design Subjects l)ost); <Jui"atiQu ~f !}le _§j:u_dy Effects 
Inulin Randomized, placebo-controlled, 8 volunteers 3-4 g/100 of inulin and wheat fiber daily No significant 
improvement in 
lipid profiles. 
Fructo-
oligosaccharides 
(FOS) 
Inulin 
L. acidophilus and B. 
longum and fructo-
oligosaccharides 
(FOS) 
double - blind and crossover for 12 weeks. 
designed study. 
Randomized, placebo-controlled, 
double-blind and crossover 
designed study. 
Randomized, placebo-controlled, 
double-blind and crossover 
designed study; with two six-
week treatment periods, 
separated by a six-week washout 
period. 
Randomized, single-blinded, 
placebo-controlled and parallel 
design trial. 
I 0 diabetic patients {6 men 
and 4 women); with plasma 
total cholesterol 4.85-5.58 
mmol/L. 
25 subjects; with baseline 
LDL-cholesterol ranging from 
3.36 to 5.17 mmol/L. 
55 normo-cholesterolemic 
volunteers. 
20 
20 g FOS/day for 4 weeks. No significant 
improvement in 
lipid profiles. 
45 g chocolate bar (containing of 18 g of No significant 
inulin) daily during treatment period. improvement in 
lipid profiles. 
3 capsules of synbiotics product 
(consisted of 109 CFU/g of L. 
acidophilus and B. longum, and 10-15 
mg ofFOS) once daily for 2 months. 
No significant 
improvement in 
lipid profiles. 
Ref 
Tarpila et 
al., 2002. 
Luo et al., 
2000. 
Davidson 
eta/., 1998. 
Greany et 
al., 2008. 
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Such contradictory findings may be attributed to various factors. Although in 
vivo trials utilize real life models with true representations of the actual pathological 
systems, these trials are also easily affected by external factors such as different strains 
of probiotics, varying types of prebiotics, dosage administered, analytical accuracy of 
lipid analyses, clinical characteristic of subjects, duration of treatment period, lack of 
statistical significant results, inadequate sample sizes, and lack of suitable control or 
placebo groups (Liong, 2007; Greany et a!., 2008). Although some of these studies 
failed to yield significant results, the reported cholesterol-lowering potential of 
probiotics and prebiotics supplementation warrants further research. 
I 
2. 7 Dose-response effects 
Although the cholesterol-lowering potential of probiotic and prebiotic has been 
widely studied, an accurate dosage administered has yet to be established. There is a 
lack of dose-response studies to determine the 'minimal effective dosage' of probiotics 
and/or prebiotics needed to reduce blood cholesterol levels. The concentration of 
probiotics in food products varies tremendously and there are currently no regulated 
standards for probiotic products to produce a cholesterol-lowering effect (FAO, 2006). A 
review of past studies has revealed that the effective administration dosages of 
probiotics vary greatly and is dependent on the strains used and the clinical 
characteristics of subjects, such as lipid profiles. Although probiotics have been 
delivered in the range of 107 to 1011 CFU/day in humans (Naruszewicz eta!., 2002) and 
107 to 109 CFU/day in animals (Ha et al., 2006; Lubbadeh eta!., 1999), some probiotics 
21 
_________________________________________________________ Chaprer2 
have been shown to be efficacious at lower levels, while some require a substantially 
higher amount to exert a cholesterol-lowering effect. 
The administration of L. plantarum 299v at a dosage of 5.0 x 107 CFU/mL (with 
consumption of 400 mL/d of a rose-hip drink) daily has been found sufficient to reduce 
LDL-cholesterol by 12% compared to the control (Naruszewicz et al., 2002). In contrast, 
the consumption of probiotic capsules containing Lactobacillus acidophilus DDS-1 and 
Bifidobacterium longum (1 09 CPU/capsule with consumption of 3 capsules in the 
morning daily) did not produce significant changes in lipid profiles (Greany et al., 
2004). This suggests that higher dosage max not necessarily translate to better effects on 
cholesterol, as compared to lower dosage. Different strains need varying dosage to 
exhibit cholesterol-lowering effects (Table 2.2). Clinically effective dosage ofprobiotics 
should only be established based on studies of the specific strains conducted in humans. 
Similar to probiotics, there is also no recommended daily dosage of prebiotics 
that specifically exert a cholesterol-lowering effect (FAO, 2007). Past studies have 
demonstrated the efficiency of various prebiotics and the combination of prebiotics and 
oligosaccharides in different dosages. While one study demonstrated the efficacy of 
lactulose and L-rhamnose in reducing fasting blood triglycerides, at dosages of 15 g/day 
and 25 g/day respectively (Vogt et. al., 2006), another study showed that 
arabinogalactan administered in dosages up to 30 g/day produced insignificant effect on 
lipid profiles (Robinson et al., 2001). It appears that the cholesterol-lowering effect is 
specific to the types of prebiotics (Table 2.3). These inconsistent findings call for more 
in-depth studies to ascertain the proper dosage of prebiotics specifically targeting a 
cholesterol-lowering effect. 
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Models 
Animal 
Table 2.2 
Dose-response effects of different pro biotic strains on lipid profiles 
Products/ Probiotics strains Animals/Subjects 
L. plantarum CK 102 (healthy human 
isolate) 
L. acidophilus (wild chickens & human 
isolates) 
L. plantarum KCTC3928 (Cell biotech Co. 
Ltd, Korea) 
Yogurt (with starter cultures); with L. 
acidophilus (Chr. Hansen Laboratorium, 
Denmark). 
20% of skimmed buffalo milk 
coprecipitate; with L. casei (National 
Collection of Microorganisms 
Unit, National Dairy Research Institute, 
Kamal, India) and Saccharomyces 
boulardii (Department of Food Science 
and Human Nutrition, UNSW, Sydney, 
Australia). 
Fermented skimmed milk; with L. casei 
strains (culture collection of the 
Department of Science and Technology, 
University of Verona, Italy). 
*32 Sprague-Dawley male 
rats; 5 weeks old; induced 
hypercholesterolemic; mean 
BW of 129±1 g. 
*30 A wassi weaning lambs; 
hypercholesterolemic; mean 
BW of 55.1±3.4 & 57.9±4.7 
kg for the treated & control 
groups, respectively. 
*21 six-week-old C57BL/6 
male mice; induced 
hypercholesterolemic. 
*60 white male mice; 
induced 
hypercholesterolemic; mean 
BW of22 g. 
*20 young Swiss male mice; 
induced 
hypercholesterolemic; mean 
BW of20 ± 2 g. 
*25 female Wistar rats with 
mean BW of 208.2 ± 8.3 g; 
induced 
hypercholesterolemic. 
Fermented whole milk; with 
acidophilus, 
L. *72 male Golden Syrian 
hamsters with age of 6-week-
Dose; duration of the 
study 
5.0 x 107 CFU!mL daily, 
6 weeks. 
1 x 109 CFU/ capsule, 2 
capsules daily, 120 days. 
1 X 109 
CFU/mL of L. plantarum 
KCTC3928, 4 weeks. 
I x 107 CFU/mL daily for 
56 days. 
1 x 106 cells/mL daily for 
42 days. 
10 mL/kg body weight of 
fermented skimmed milk 
(containing 9.3 log10 
CFU/mL of L. casei) 
daily for 10 days. 
Fermented whole milk 
(containing 1 X 105-6 
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Effects 
TC: 27.9% decrease (P< 0.05) 
LDL-C: 28.7% decrease (P< 0.05) 
TG: 61.6% decrease (P < 0.05) 
TC: 22.6% decrease (P < 0.05) 
[treatment group with mean plasma 
TC of 72.8±5.7 mg/100 mL; 
control group with mean plasma 
TC of94.0±7.8 mg/100 mL] 
TC: 33% decrease (P < 0.05) 
LDL-C: 42% decrease (P < 0.05) 
TG: 32% decrease (P < 0.05) 
HDL-C: 35% increase (P < 0.05) 
TC: 31.0% decrease (P< 0.01) 
LDL-C: 51.4% decrease (P< 0.01) 
TC: 17.9% decrease (P < 0.05) 
LDL-C: 35.6% decrease (P < 0.05) 
TG: 8.9% decrease (P< 0.05) 
HDL-C: 6.0% increase (P < 0.05) 
TC: 13.5% decrease 
TG: 39% decrease (P < 0.05) 
HDL-C: 10.7% increase 
TC: 37.5% decrease (P< 0.001) 
LDL-C: 50.9% decrease (P < 
Ref 
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Lubbadeh et al., 
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Akalin et al., 
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Sindhu and 
Khetarpaul, 
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Bertazzoni-
Minelli et 
2004. 
Chien et 
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al., 
Human 
Bifidobacterium lactis, St. thermophilus 
and Lactobacillus 
bulgaricus. 
Kefir; with Lactococcus lactis subsp. 
lac tis, Lactococcus lac tis subsp. cremoris, 
St. lactis subsp. diacetyiactis, St. salivarius 
subsp. thermophilus, Leuconostoc 
cremoris, Lactobacillus 
delbrueckii subsp. bulgarics, Lactobacillus 
delbrueckii subsp. lactis, Lactobacillus 
acidophilus, Lactobacillus casei,. 
Lactobacillus helveticus and 
Saccharomyces cerevisiae. 
L. plantarum 299v (Pro Viva) 
Enterococcus 
faecium & 2 strains of Streptococcus 
thermophilus (Causido®; Gaio®) 
old; mean BW of 107.8 ± 2.8 
g; induced 
hypercholesterolemic. 
*18 male Wister rats 
weighing 280-300 g; induced 
hypercholesterolemic. 
*36 healthy volunteers with 
moderately elevated 
fibrinogen concentrations 
(>3.0 g/L); 35-45 years old; 
mean TC of 5.59±0.88 
mmol/L for treatment group 
& 5.51±0.75 mmol/L for 
control group. 
**32 patients; 36-65 years 
old; mean TC of 
248.47±26.75 mg/dl, mean 
LDL-C of 172.22±21.17 
CFU/mL of probiotic 0.001) 
mixture) daily for 28 
days. 
5% of mixed probiotic TC: 31.6% decrease (P < 0.05) 
cultures in kefir daily for 
14 days. 
400 mL of rose-hip drink TC: 2.5% decrease 
containing 5.0 x 107 LDL-C: 7.9% decrease 
CFU/mL daily, 6 weeks. 
200 g of Gaio® 
containing 105-109 /mL of 
E.faecium & 5-20 x 108 
/mL of S. 
TC: 5.3% decrease (P = 0.004) 
LDL-C: 6.15% decrease (P = 
0.012) 
mg/dl. thermophilus daily, 16 
weeks. 
Tarnai 
1995. 
et al., 
N aruszewicz et 
al., 2002. 
Bertolami eta!., 
1999. 
TC: Total cholesterol; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; TG: triglycerides; BW: body weight 
*Experimental design: Randomized, placebo-controlled, double-blind and parallel 
**Experimental design: Randomized, placebo-controlled, double-blind and crossover 
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